DK1855677T3 - 3,11 B-CIS-dihydrotetrabanezin til behandling af skizofreni og andre psykoser - Google Patents
3,11 B-CIS-dihydrotetrabanezin til behandling af skizofreni og andre psykoserInfo
- Publication number
- DK1855677T3 DK1855677T3 DK06765238T DK06765238T DK1855677T3 DK 1855677 T3 DK1855677 T3 DK 1855677T3 DK 06765238 T DK06765238 T DK 06765238T DK 06765238 T DK06765238 T DK 06765238T DK 1855677 T3 DK1855677 T3 DK 1855677T3
- Authority
- DK
- Denmark
- Prior art keywords
- psychoses
- schizophrenia
- cis
- treatment
- dihydrotetrabenzene
- Prior art date
Links
- 208000028017 Psychotic disease Diseases 0.000 title abstract 2
- 201000000980 schizophrenia Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0516167.4A GB0516167D0 (en) | 2005-08-06 | 2005-08-06 | Pharmaceutical compounds |
| GB0516790A GB0516790D0 (en) | 2005-08-16 | 2005-08-16 | Pharmaceutical compounds |
| PCT/GB2006/002936 WO2007017654A1 (en) | 2005-08-06 | 2006-08-04 | 3, hb cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1855677T3 true DK1855677T3 (da) | 2009-02-09 |
Family
ID=37400949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06765238T DK1855677T3 (da) | 2005-08-06 | 2006-08-04 | 3,11 B-CIS-dihydrotetrabanezin til behandling af skizofreni og andre psykoser |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20110257220A1 (enExample) |
| EP (2) | EP1855677B1 (enExample) |
| JP (1) | JP2009504622A (enExample) |
| KR (1) | KR20080033500A (enExample) |
| AT (2) | ATE415968T1 (enExample) |
| AU (1) | AU2006277753B2 (enExample) |
| CA (1) | CA2620960A1 (enExample) |
| CY (1) | CY1108843T1 (enExample) |
| DE (1) | DE602006004009D1 (enExample) |
| DK (1) | DK1855677T3 (enExample) |
| ES (1) | ES2318771T3 (enExample) |
| HR (1) | HRP20090074T3 (enExample) |
| MX (1) | MX2008001549A (enExample) |
| NZ (1) | NZ566011A (enExample) |
| PL (1) | PL1855677T3 (enExample) |
| PT (1) | PT1855677E (enExample) |
| RS (1) | RS50807B (enExample) |
| RU (1) | RU2407743C2 (enExample) |
| SI (1) | SI1855677T1 (enExample) |
| WO (1) | WO2007017654A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8039627B2 (en) | 2006-11-08 | 2011-10-18 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
| US8008500B2 (en) | 2007-06-08 | 2011-08-30 | General Electric Company | Intermediates useful for making tetrabenazine compounds |
| US8053578B2 (en) | 2007-11-29 | 2011-11-08 | General Electric Company | Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes |
| GB0810857D0 (en) * | 2008-06-13 | 2008-07-23 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| GB2463451A (en) * | 2008-09-08 | 2010-03-17 | Cambridge Lab | 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia |
| GB2463283A (en) * | 2008-09-08 | 2010-03-10 | Cambridge Lab | 3,11b-cis-dihydrotetrabenazine for use in treating asthma |
| WO2011153157A2 (en) | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2012135595A2 (en) | 2011-04-01 | 2012-10-04 | 3M Innovative Properties Company | Films including triazine-based ultraviolet absorbers |
| KR20160111999A (ko) | 2014-01-27 | 2016-09-27 | 오스펙스 파마슈티칼스, 인코포레이티드 | 소포성 모노아민 수송체 2의 벤조퀴놀린 억제제 |
| CN113413385A (zh) * | 2014-02-07 | 2021-09-21 | 纽罗克里生物科学有限公司 | 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途 |
| HRP20240304T1 (hr) | 2015-10-30 | 2024-05-10 | Neurocrine Biosciences, Inc. | Soli valbenazin dihidroklorida i njihovi polimorfi |
| LT3394057T (lt) | 2015-12-23 | 2022-06-27 | Neurocrine Biosciences, Inc. | Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą) |
| EP4400171A3 (en) * | 2016-12-02 | 2024-09-11 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating schizophrenia or schizoaffective disorder |
| KR20190108146A (ko) | 2017-01-27 | 2019-09-23 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| IL309802A (en) | 2017-09-21 | 2024-02-01 | Neurocrine Biosciences Inc | High dose valbenazine formulation and related preparations, methods and kits |
| JP2021502959A (ja) | 2017-10-10 | 2021-02-04 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| JOP20200336A1 (ar) | 2018-08-15 | 2020-12-22 | Neurocrine Biosciences Inc | طرق إعطاء مثبطات vmat2 معينة |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2830993A (en) * | 1958-04-15 | Quinolizine derivatives | ||
| US2843591A (en) | 1958-07-15 | Method for preparing same | ||
| CA2058640A1 (en) * | 1991-01-25 | 1992-07-26 | Richard R. Scherschlicht | Tricyclic pyridone derivative |
| US6087376A (en) * | 1997-02-05 | 2000-07-11 | University Of Kentucky Research Foundation | Use of lobeline compounds in the treatment of central nervous system diseases and pathologies |
| FR2770215B1 (fr) * | 1997-10-28 | 2000-01-14 | Pf Medicament | Derives d'aminomethyl-benzo[a]quinolizidine, leur preparation et leur application en therapeutique pour les maladies neurodegeneratives |
| GB2410947B (en) * | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
-
2006
- 2006-08-04 EP EP06765238A patent/EP1855677B1/en active Active
- 2006-08-04 AT AT06765238T patent/ATE415968T1/de active
- 2006-08-04 WO PCT/GB2006/002936 patent/WO2007017654A1/en not_active Ceased
- 2006-08-04 PL PL06765238T patent/PL1855677T3/pl unknown
- 2006-08-04 PT PT06765238T patent/PT1855677E/pt unknown
- 2006-08-04 SI SI200630210T patent/SI1855677T1/sl unknown
- 2006-08-04 MX MX2008001549A patent/MX2008001549A/es active IP Right Grant
- 2006-08-04 DK DK06765238T patent/DK1855677T3/da active
- 2006-08-04 DE DE602006004009T patent/DE602006004009D1/de active Active
- 2006-08-04 RU RU2008108623/04A patent/RU2407743C2/ru not_active IP Right Cessation
- 2006-08-04 EP EP08170385A patent/EP2050451B1/en active Active
- 2006-08-04 RS RSP-2009/0055A patent/RS50807B/sr unknown
- 2006-08-04 AT AT08170385T patent/ATE534391T1/de active
- 2006-08-04 JP JP2008525620A patent/JP2009504622A/ja not_active Ceased
- 2006-08-04 HR HR20090074T patent/HRP20090074T3/xx unknown
- 2006-08-04 AU AU2006277753A patent/AU2006277753B2/en not_active Expired - Fee Related
- 2006-08-04 CA CA002620960A patent/CA2620960A1/en not_active Abandoned
- 2006-08-04 US US11/997,591 patent/US20110257220A1/en not_active Abandoned
- 2006-08-04 NZ NZ566011A patent/NZ566011A/en not_active IP Right Cessation
- 2006-08-04 KR KR1020087005308A patent/KR20080033500A/ko not_active Withdrawn
- 2006-08-04 ES ES06765238T patent/ES2318771T3/es active Active
-
2009
- 2009-02-26 CY CY20091100221T patent/CY1108843T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006277753B2 (en) | 2011-11-10 |
| AU2006277753A1 (en) | 2007-02-15 |
| PL1855677T3 (pl) | 2009-07-31 |
| EP1855677A1 (en) | 2007-11-21 |
| ATE415968T1 (de) | 2008-12-15 |
| CA2620960A1 (en) | 2007-02-15 |
| HRP20090074T3 (en) | 2009-04-30 |
| WO2007017654A1 (en) | 2007-02-15 |
| SI1855677T1 (sl) | 2009-04-30 |
| CY1108843T1 (el) | 2014-07-02 |
| RU2008108623A (ru) | 2009-09-20 |
| ES2318771T3 (es) | 2009-05-01 |
| EP2050451B1 (en) | 2011-11-23 |
| NZ566011A (en) | 2011-01-28 |
| EP1855677B1 (en) | 2008-12-03 |
| US20110257220A1 (en) | 2011-10-20 |
| JP2009504622A (ja) | 2009-02-05 |
| RS50807B (sr) | 2010-08-31 |
| DE602006004009D1 (de) | 2009-01-15 |
| MX2008001549A (es) | 2008-04-04 |
| EP2050451A1 (en) | 2009-04-22 |
| KR20080033500A (ko) | 2008-04-16 |
| ATE534391T1 (de) | 2011-12-15 |
| RU2407743C2 (ru) | 2010-12-27 |
| HK1111083A1 (en) | 2008-08-01 |
| PT1855677E (pt) | 2009-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1855677T3 (da) | 3,11 B-CIS-dihydrotetrabanezin til behandling af skizofreni og andre psykoser | |
| FIC20210022I1 (fi) | tukatinibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan tai solvaatin muodossa | |
| NO20070470L (no) | Sammensetninger og fremgangsmater for behandling av dyslipidemi | |
| DK1487444T3 (da) | Anvendelse af pyridylamider som angiogeneseinhibitorer | |
| NO20091955L (no) | Antivirale sammensetninger, og fremgangsmater for anvendelse | |
| LT2878297T (lt) | Medikamentai, skirti fibrozinių ligų gydymui arba prevencijai | |
| SE0203825D0 (sv) | Novel fused heterocycles and uses thereof | |
| ZA200801170B (en) | 3,11B-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation | |
| CY1110027T1 (el) | Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων | |
| TW200616977A (en) | Enantiomers of selected fused heterocyclics and uses thereof | |
| PT2366393E (pt) | Roflumilaste para o tratamento da hipertensão pulmonar | |
| TN2012000111A1 (en) | Compounds useful against kinetoplastideae parasites | |
| TW200621260A (en) | Selected fused heterocyclics and uses thereof | |
| ATE511512T1 (de) | Olanzapinpamoat-dihydrat | |
| DK1523985T3 (da) | Ikke-radioaktivt strontiumholdigt middel til behandling af kræft | |
| CY1111067T1 (el) | Χρηση της ν-(διβενζ (β,f) οξεπιν-10-υλμεθυλ) -ν-μεθυλ-ν-προπ-2-υνυλαμινης (omigapil) στην προληψη και/ή την θεραπεια της μυϊκης δυστροφiας | |
| ATE411310T1 (de) | Reinigungsverfahren von moxonidine | |
| GB0513835D0 (en) | HIV inhibitors | |
| DK1951718T3 (da) | 4-Oxadiazolyl-piperidinforbindelser og anvendelse deraf |